세계의 근육 소모성 질환 시장 : 성장, 전망, 경쟁 분석(2024-2032년)

Muscle wasting disorders, characterized by the significant reduction of muscle mass and strength, have been the subject of increased medical attention over recent years. These conditions encompass a variety of diseases ranging from sarcopenia, typically related to aging, to neuromuscular disorders like muscular dystrophy. The muscle wasting disorders market is estimated to grow at a CAGR of 15.5% from 2024 to 2032.

Driver: Increasing Aging Population and Associated Sarcopenia

One of the primary drivers for the muscle wasting disorders market is the exponential rise in the global aging population. As the baby boomer generation enters the senior age bracket, the prevalence of sarcopenia - a muscle wasting condition closely associated with aging - has surged. According to the United Nations' report on World Population Aging, the number of individuals aged 60 years or older is expected to double by 2050. This demographic shift has led to an uptick in cases of sarcopenia. Compounded by the fact that muscle wasting exponentially increases the risk of physical disabilities, falls, fractures, and overall mortality, the healthcare industry's focus on combating this disorder has intensified. Treatment strategies ranging from hormone replacement therapies to strength training regimens have garnered attention, signifying the market's expansive potential.

Opportunity: Advancements in Genetic Therapies for Neuromuscular Disorders

The realm of genetic therapies has showcased promising results in addressing the root causes of certain muscle wasting disorders, especially those of a hereditary nature like muscular dystrophy. Recent case studies highlight instances where gene therapies have been successful in introducing or correcting specific genes, leading to improved muscle function and reduced disease progression. For instance, a publication in the New England Journal of Medicine detailed a gene therapy trial that demonstrated improved motor functions in children with a specific type of muscular dystrophy. As genetic research continues to unveil the underlying mutations causing these disorders, the opportunity to develop targeted therapies expands, potentially revolutionizing the treatment landscape.

Restraint: High Treatment Costs and Limited Accessibility

While advancements in treatment and management are promising, they come at a steep price. The costs associated with cutting-edge treatments, especially genetic therapies, are exorbitant. Many of these treatments are not universally covered by insurance, placing a significant financial burden on patients. Furthermore, the limited availability of specialized treatment centers, primarily in low-to-middle-income countries, restricts access to care. A study in the Journal of Clinical Medicine emphasized the significant disparities in the availability of neuromuscular disorder treatments across different regions, elucidating the market's challenges in achieving global reach.

Challenge: Variability in Clinical Presentation and Diagnostic Difficulties

Muscle wasting disorders present with a wide variability in clinical symptoms, often making early diagnosis challenging. Given that timely intervention is crucial to manage progression, this diagnostic delay can lead to compromised patient outcomes. Muscle biopsies, one of the gold standards in diagnosing certain muscle-wasting disorders, are invasive and might not always provide conclusive results. An article in the Muscle & Nerve journal highlighted instances where muscle biopsies yielded non-specific results, necessitating further diagnostic procedures. This variability not only prolongs the diagnostic journey but also amplifies the emotional and financial distress associated with these disorders.

Market Segmentation by Type

In terms of revenue generation, muscular dystrophy led the market segment in 2023. This can be attributed to its prevalence, especially in the pediatric population, and the high costs associated with its management, which include physiotherapy, surgical interventions, and medications. The research focus on dystrophic conditions, especially Duchenne Muscular Dystrophy (DMD), has paved the way for innovations in treatments like gene therapies and exon skipping drugs, further pushing the revenue envelope. In contrast, muscular atrophy, often a consequence of neuromuscular diseases or conditions like ALS, spinal muscular atrophy, or nerve injuries, demonstrated the highest Compound Annual Growth Rate (CAGR). The rising awareness, early diagnostic interventions, and burgeoning therapeutic pipelines for conditions like Spinal Muscular Atrophy (SMA) contribute to this growth trajectory, expected to continue from 2024 to 2032.

Market Segmentation by End-User

In 2023, hospitals emerged as the principal revenue contributor for the muscle wasting disorders market. This dominance was attributed to the comprehensive care offered, including diagnostics, therapeutics, surgeries, and rehabilitation, all under one roof. As multidisciplinary approaches became essential for managing these disorders, hospitals' holistic care model was preferred. However, from 2024 to 2032, it's expected that rehab centers will showcase the highest CAGR. As the emphasis shifts towards improving quality of life, maintaining mobility, and delaying disease progression, the role of rehabilitative therapies in muscle wasting disorders management becomes paramount. These centers, specializing in physiotherapy, occupational therapy, and speech therapy, among others, are becoming increasingly pivotal. Specialty clinics, focusing on niche therapeutic areas, and other segments like home care also play crucial roles, with patients seeking personalized, specialized care or preferring treatments within the comfort of their homes.

Market Segmentation by Region

North America, with its advanced healthcare infrastructure, research initiatives, and patient awareness, held the largest revenue share in 2023. The FDA's approval of drugs for conditions like DMD and SMA, coupled with the presence of major pharmaceutical players, propelled the region's dominance. However, the Asia-Pacific region is anticipated to exhibit the highest CAGR from 2024 to 2032. Factors like increasing healthcare expenditure, rising awareness of muscle wasting disorders, and improving diagnostic infrastructure contribute to this forecasted growth. Moreover, the burgeoning population and the presence of untapped markets present lucrative opportunities for market expansion in this region.

Competitive Trends

The muscle wasting disorders market is characterized by intense competition, with major players like Biogen, Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Nippon Shinyaku Co., Ltd. (NS Pharma, Inc.), PTC Therapeutics, Inc., and Teva Pharmaceutical Industries Ltd. leading the charge in 2023. These companies primarily focused on strategies like mergers, acquisitions, research collaborations, and aggressive R&D investments to maintain their market positions. For instance, Roche's acquisition of Spark Therapeutics accentuated its foothold in the gene therapy arena, especially concerning muscle wasting disorders. Additionally, the emphasis on patient assistance programs, ensuring drug accessibility even with high costs, became a notable strategy. Moving forward, from 2024 to 2032, it's expected that these players will continue their innovations, collaborations, and strategic alliances, driving the market forward.

Historical & Forecast Period

This study report represents an analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Muscle Wasting Disorders market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Muscle Wasting Disorders market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

Market Segmentation

Type

• Muscular Dystrophy
• Duchenne Muscular Dystrophy (DMD)
• Becker Muscular Dystrophy (BMD)
• Myotonic Muscular Dystrophy
• Congenital Muscular Dystrophy
• Limb-Girdle Muscular Dystrophy
• Others (Oculopharyngeal Muscular Dystrophy, Emery-Dreifuss Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, etc.)
  • Muscular Atrophy
• Physiologic Atrophy
• Pathologic Atrophy
• Neurogenic Atrophy

Treatment Type

• Medications
• Physical Therapy
• Ultrasound Therapy
• Electric Simulation
  • Nutritional Therapy
  • Surgery
  • Gene Therapy
  • Others (Occupational Therapy, Respiratory Therapy, Assistive Devices, etc.)

End-User

• Hospitals
• Rehab Centers
• Specialty Clinics
• Others (Homecare, etc.)

Region Segment (2022-2032; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Muscle Wasting Disorders market?

What are the key investment pockets concerning product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2032.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Muscle Wasting Disorders market?

Which is the largest regional market for Muscle Wasting Disorders market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Muscle Wasting Disorders market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Muscle Wasting Disorders market worldwide?

Table of Contents

1. Preface

• 1.1. Report Description
  • 1.1.1. Purpose of the Report
  • 1.1.2. Target Audience
  • 1.1.3. Key Offerings
• 1.2. Market Segmentation
• 1.3. Research Methodology
  • 1.3.1. Phase I - Secondary Research
  • 1.3.2. Phase II - Primary Research
  • 1.3.3. Phase III - Expert Panel Review
  • 1.3.4. Assumptions
  • 1.3.5. Approach Adopted

2. Executive Summary

• 2.1. Market Snapshot: Global Muscle Wasting Disorders Market
• 2.2. Global Muscle Wasting Disorders Market, By Type, 2023 (US$ Million)
• 2.3. Global Muscle Wasting Disorders Market, By Treatment Type, 2023 (US$ Million)
• 2.4. Global Muscle Wasting Disorders Market, By End-User, 2023 (US$ Million)
• 2.5. Global Muscle Wasting Disorders Market, By Geography, 2023 (US$ Million)
• 2.6. Attractive Investment Proposition by Geography, 2023

3. Muscle Wasting Disorders Market: Competitive Analysis

• 3.1. Market Positioning of Key Muscle Wasting Disorders Market Vendors
• 3.2. Strategies Adopted by Muscle Wasting Disorders Market Vendors
• 3.3. Key Industry Strategies
• 3.4. Tier Analysis 2023 Versus 2032

4. Muscle Wasting Disorders Market: Macro Analysis & Market Dynamics

• 4.1. Introduction
• 4.2. Global Muscle Wasting Disorders Market Value, 2022 - 2032, (US$ Million)
• 4.3. Market Dynamics
  • 4.3.1. Market Drivers
  • 4.3.2. Market Restraints
  • 4.3.3. Key Challenges
  • 4.3.4. Key Opportunities
• 4.4. Impact Analysis of Drivers and Restraints
• 4.5. See-Saw Analysis
• 4.6. Porter's Five Force Model
  • 4.6.1. Supplier Power
  • 4.6.2. Buyer Power
  • 4.6.3. Threat Of Substitutes
  • 4.6.4. Threat Of New Entrants
  • 4.6.5. Competitive Rivalry
• 4.7. PESTEL Analysis
  • 4.7.1. Political Landscape
  • 4.7.2. Economic Landscape
  • 4.7.3. Technology Landscape
  • 4.7.4. Legal Landscape
  • 4.7.5. Social Landscape

5. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)

• 5.1. Market Overview
• 5.2. Growth & Revenue Analysis: 2023 Versus 2032
• 5.3. Market Segmentation
  • 5.3.1. Muscular Dystrophy
    • 5.3.1.1. Duchenne Muscular Dystrophy (DMD)
    • 5.3.1.2. Becker Muscular Dystrophy (BMD)
    • 5.3.1.3. Myotonic Muscular Dystrophy
    • 5.3.1.4. Congenital Muscular Dystrophy
    • 5.3.1.5. Limb-Girdle Muscular Dystrophy
    • 5.3.1.6. Others (Oculopharyngeal Muscular Dystrophy, Emery-Dreifuss Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, etc.)
  • 5.3.2. Muscular Atrophy
    • 5.3.2.1. Physiologic Atrophy
    • 5.3.2.2. Pathologic Atrophy
    • 5.3.2.3. Neurogenic Atrophy

6. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)

• 6.1. Market Overview
• 6.2. Growth & Revenue Analysis: 2023 Versus 2032
• 6.3. Market Segmentation
  • 6.3.1. Medications
  • 6.3.2. Physical Therapy
    • 6.3.2.1. Ultrasound Therapy
    • 6.3.2.2. Electric Simulation
  • 6.3.3. Nutritional Therapy
  • 6.3.4. Surgery
  • 6.3.5. Gene Therapy
  • 6.3.6. Others (Occupational Therapy, Respiratory Therapy, Assistive Devices, etc.)

7. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

• 7.1. Market Overview
• 7.2. Growth & Revenue Analysis: 2023 Versus 2032
• 7.3. Market Segmentation
  • 7.3.1. Hospitals
  • 7.3.2. Rehab Centers
  • 7.3.3. Specialty Clinics
  • 7.3.4. Others (Homecare, etc.)

8. North America Muscle Wasting Disorders Market, 2022-2032, USD (Million)

• 8.1. Market Overview
• 8.2. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
• 8.3. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
• 8.4. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
• 8.5.Muscle Wasting Disorders Market: By Region, 2022-2032, USD (Million)
  • 8.5.1.North America
    • 8.5.1.1. U.S.
      • 8.5.1.1.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 8.5.1.1.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 8.5.1.1.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 8.5.1.2. Canada
      • 8.5.1.2.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 8.5.1.2.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 8.5.1.2.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 8.5.1.3. Rest of North America
      • 8.5.1.3.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 8.5.1.3.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 8.5.1.3.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

9. UK and European Union Muscle Wasting Disorders Market, 2022-2032, USD (Million)

• 9.1. Market Overview
• 9.2. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
• 9.3. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
• 9.4. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
• 9.5.Muscle Wasting Disorders Market: By Region, 2022-2032, USD (Million)
  • 9.5.1.UK and European Union
    • 9.5.1.1. UK
      • 9.5.1.1.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 9.5.1.1.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 9.5.1.1.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 9.5.1.2. Germany
      • 9.5.1.2.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 9.5.1.2.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 9.5.1.2.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 9.5.1.3. Spain
      • 9.5.1.3.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 9.5.1.3.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 9.5.1.3.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 9.5.1.4. Italy
      • 9.5.1.4.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 9.5.1.4.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 9.5.1.4.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 9.5.1.5. France
      • 9.5.1.5.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 9.5.1.5.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 9.5.1.5.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 9.5.1.6. Rest of Europe
      • 9.5.1.6.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 9.5.1.6.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 9.5.1.6.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

10. Asia Pacific Muscle Wasting Disorders Market, 2022-2032, USD (Million)

• 10.1. Market Overview
• 10.2. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
• 10.3. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
• 10.4. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
• 10.5.Muscle Wasting Disorders Market: By Region, 2022-2032, USD (Million)
  • 10.5.1.Asia Pacific
    • 10.5.1.1. China
      • 10.5.1.1.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 10.5.1.1.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 10.5.1.1.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 10.5.1.2. Japan
      • 10.5.1.2.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 10.5.1.2.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 10.5.1.2.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 10.5.1.3. India
      • 10.5.1.3.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 10.5.1.3.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 10.5.1.3.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 10.5.1.4. Australia
      • 10.5.1.4.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 10.5.1.4.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 10.5.1.4.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 10.5.1.5. South Korea
      • 10.5.1.5.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 10.5.1.5.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 10.5.1.5.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 10.5.1.6. Rest of Asia Pacific
      • 10.5.1.6.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 10.5.1.6.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 10.5.1.6.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

11. Latin America Muscle Wasting Disorders Market, 2022-2032, USD (Million)

• 11.1. Market Overview
• 11.2. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
• 11.3. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
• 11.4. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
• 11.5.Muscle Wasting Disorders Market: By Region, 2022-2032, USD (Million)
  • 11.5.1.Latin America
    • 11.5.1.1. Brazil
      • 11.5.1.1.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 11.5.1.1.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 11.5.1.1.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 11.5.1.2. Mexico
      • 11.5.1.2.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 11.5.1.2.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 11.5.1.2.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 11.5.1.3. Rest of Latin America
      • 11.5.1.3.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 11.5.1.3.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 11.5.1.3.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

12. Middle East and Africa Muscle Wasting Disorders Market, 2022-2032, USD (Million)

• 12.1. Market Overview
• 12.2. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
• 12.3. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
• 12.4. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
• 12.5.Muscle Wasting Disorders Market: By Region, 2022-2032, USD (Million)
  • 12.5.1.Middle East and Africa
    • 12.5.1.1. GCC
      • 12.5.1.1.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 12.5.1.1.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 12.5.1.1.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 12.5.1.2. Africa
      • 12.5.1.2.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 12.5.1.2.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 12.5.1.2.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 12.5.1.3. Rest of Middle East and Africa
      • 12.5.1.3.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 12.5.1.3.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 12.5.1.3.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

13. Company Profile

• 13.1. Biogen, Inc.
  • 13.1.1. Company Overview
  • 13.1.2. Financial Performance
  • 13.1.3. Product Portfolio
  • 13.1.4. Strategic Initiatives
• 13.2. F. Hoffmann-La Roche Ltd
  • 13.2.1. Company Overview
  • 13.2.2. Financial Performance
  • 13.2.3. Product Portfolio
  • 13.2.4. Strategic Initiatives
• 13.3. Novartis AG
  • 13.3.1. Company Overview
  • 13.3.2. Financial Performance
  • 13.3.3. Product Portfolio
  • 13.3.4. Strategic Initiatives
• 13.4. Ionis Pharmaceuticals, Inc.
  • 13.4.1. Company Overview
  • 13.4.2. Financial Performance
  • 13.4.3. Product Portfolio
  • 13.4.4. Strategic Initiatives
• 13.5. Sarepta Therapeutics, Inc.
  • 13.5.1. Company Overview
  • 13.5.2. Financial Performance
  • 13.5.3. Product Portfolio
  • 13.5.4. Strategic Initiatives
• 13.6. Nippon Shinyaku Co., Ltd. (NS Pharma, Inc.)
  • 13.6.1. Company Overview
  • 13.6.2. Financial Performance
  • 13.6.3. Product Portfolio
  • 13.6.4. Strategic Initiatives
• 13.7. PTC Therapeutics, Inc.
  • 13.7.1. Company Overview
  • 13.7.2. Financial Performance
  • 13.7.3. Product Portfolio
  • 13.7.4. Strategic Initiatives
• 13.8. Teva Pharmaceutical Industries Ltd.
  • 13.8.1. Company Overview
  • 13.8.2. Financial Performance
  • 13.8.3. Product Portfolio
  • 13.8.4. Strategic Initiatives
• 13.9. Other Notable Players
  • 13.9.1. Company Overview
  • 13.9.2. Financial Performance
  • 13.9.3. Product Portfolio
  • 13.9.4. Strategic Initiatives